

# Richard Adams

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9055743/publications.pdf>

Version: 2024-02-01

14  
papers

190  
citations

1306789

7  
h-index

1125271

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

264  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring. <i>Journal of Clinical Oncology</i> , 2021, 39, 3705-3715.	0.8	51
2	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
3	Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. <i>European Journal of Cancer</i> , 2018, 102, 31-39.	1.3	25
4	Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3693-3704.	0.8	19
5	BRAF V600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1386-1395.	3.0	17
6	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	3.0	12
7	HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 944-954.	3.0	11
8	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). <i>Radiation Oncology</i> , 2021, 16, 163.	1.2	9
9	Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. <i>Clinical Trials</i> , 2022, 19, 146-157.	0.7	7
10	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110205.	1.4	3
11	Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
12	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
13	A Road Map for Designing Phase I Clinical Trials of Radiotherapy Novel Agent Combinations. <i>Clinical Cancer Research</i> , 2022, 28, 3639-3651.	3.2	2
14	Reply to A. Kurreck et al and M.S. Copur et al. <i>Journal of Clinical Oncology</i> , 2022, 40, 1263-1264.	0.8	0